Olanzapine
- Generic Name
- Olanzapine
- Brand Names
- Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N4S
- CAS Number
- 132539-06-1
- Unique Ingredient Identifier
- N7U69T4SZR
- Background
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...
- Indication
Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...
- Associated Conditions
- Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Olanzapine for Nausea After Surgery
- Conditions
- Interventions
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Jaime B Hyman
- Target Recruit Count
- 180
- Registration Number
- NCT02755116
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 1098
- Registration Number
- NCT02717195
- Locations
- 🇧🇬
BG1029, Veliko Tŭrnovo, Bulgaria
🇲🇽MX1011, Guadalajara, Mexico
🇲🇽MX1022, Guadalajara, Mexico
Molecular Mechanisms of Antipsychotic-induced Insulin Resistance
- Conditions
- Interventions
- First Posted Date
- 2016-03-15
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Wayne State University
- Target Recruit Count
- 31
- Registration Number
- NCT02708394
- Locations
- 🇺🇸
Wayne State University Clinical Research Center, Detroit, Michigan, United States
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 561
- Registration Number
- NCT02694328
- Locations
- 🇵🇷
Alkermes Investigational Site, San Juan, Puerto Rico
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment
- Conditions
- Interventions
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Shanxi Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT02650102
- Locations
- 🇨🇳
First Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi, China
Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
- Conditions
- Interventions
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Hennepin Healthcare Research Institute
- Target Recruit Count
- 70
- Registration Number
- NCT02643355
- Locations
- 🇺🇸
Hennepin County Medical Center, Minneapolis, Minnesota, United States
Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
- Conditions
- Interventions
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- Augusta University
- Target Recruit Count
- 108
- Registration Number
- NCT02635984
- Locations
- 🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 403
- Registration Number
- NCT02634346
- Locations
- 🇺🇦
Alkermes Investigational Site, Vinnytsia, Ukraine
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
- Conditions
- Interventions
- Other: Caregiver psycho-education and skills trainingOther: Caregiver support available at the study siteDrug: Paliperidone palmitateDrug: ChlorpromazineDrug: DroperidolDrug: FluphenazineDrug: HaloperidolDrug: LoxapineDrug: PerphenazineDrug: PimozideDrug: ProchlorperazineDrug: ThiothixeneDrug: ThioridazineDrug: TrifluoperazineDrug: AripiprazoleDrug: AsenapineDrug: ClozapineDrug: IloperidoneDrug: OlanzapineDrug: PaliperidoneDrug: QuetiapineDrug: RisperidoneDrug: Ziprasidone
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 296
- Registration Number
- NCT02600741
Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana
- Conditions
- Interventions
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- University of Ghana Medical School
- Target Recruit Count
- 139
- Registration Number
- NCT02593734
- Locations
- 🇬🇭
Mount Horeb Prayer Centre, Mamfe, Ghana
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.